Studies Highlight Role of bcl-2 Gene in Programmed Cell Death

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

SAN DIEGO--The bcl-2 gene, present in follicular-type B cell lymph-oma, serves as a critical checkpoint in the apoptosis pathway, and may be involved in the development of ultraviolet-induced skin cancers, in combination with the tumor-suppressor gene p53, according to two reports presented at the American Association for Cancer Research (AACR) annual meeting.

SAN DIEGO--The bcl-2 gene, present in follicular-type B cell lymph-oma,serves as a critical checkpoint in the apoptosis pathway, and may be involvedin the development of ultraviolet-induced skin cancers, in combinationwith the tumor-suppressor gene p53, according to two reports presentedat the American Association for Cancer Research (AACR) annual meeting.

The bcl-2 apoptosis-suppressor gene is complemented by another gene,known as bax, which is involved in stimulating apoptosis, Stanley J. Korsmeyer,MD, said at the meeting in the 36th Annual Clowes Memorial Award lecture.When bax predominates, cells execute a programmed death command, but whenbcl-2 is excessive, the program is interrupted and cells survive.

In their studies of bcl-2-deficient mice, Dr. Korsmeyer and his colleaguesat the Howard Hughes Medical Institute at Washington University Schoolof Medicine, St. Louis, found that the mice embryos developed normally.However, when these bcl-2-deficient mice reached adulthood, the bax genepredominated, leading to massive death of lymphocytes and the disappearanceof lymphoid organs.

In contrast, in bax-deficient mice, bcl-2 predominated. These mice displayedcellular hyperplasia and aberrations in cell death during the developmentof the testes.

"Further study of the bcl-2 family holds the promise of improvingour understanding of the pathway of programmed cell death and the aberrationsin this process that result in malignancy," Dr. Korsmeyer said.

UV Radiation-Induced Apoptosis

In other research, investigators from the Department of Dermatologyat Mount Sinai School of Medicine, New York, hypothesized that ultravioletA (UVA) radiation and ultraviolet B (UVB) radiation could induce apoptosisby stimulating p53 or by downregulating the expression of bcl-2.

Using a cell line that expresses both p53 and bcl-2, the New York Cityinvestigators found that UVB radiation significantly induced the expressionof p53 in a dose-dependent and time-dependent manner. Exposure to an equallycytotoxic dose of UVA radiation, however, produced no effects on p53 expression.

In contrast, UVA radiation substantially down-regulated the expressionof bcl-2, whereas exposure to the same level of UVB radiation producedno change in bcl-2 expression.

Different Pathways Triggered

The researchers concluded that UVA and UVB radiation cause cell damageand induce apoptosis by triggering different signal transduction pathways,and that the balance between the expression of p53 and bcl-2 plays an importantrole in regulating ultraviolet radiation-induced apoptosis.

Said investigator Huachen Wei, MD, PhD: "Because mutations in p53and overexpression of bcl-2 can result in human cancers, our findings suggestthat ultraviolet radiation may provide a new approach for drug development."

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content